Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 299

1.

Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.

Heyndrickx L, Stewart-Jones G, Jansson M, Schuitemaker H, Bowles E, Buonaguro L, Grevstad B, Vinner L, Vereecken K, Parker J, Ramaswamy M, Biswas P, Vanham G, Scarlatti G, Fomsgaard A; NGIN Consortium.

PLoS One. 2013 Sep 2;8(9):e74552. doi: 10.1371/journal.pone.0074552. eCollection 2013.

2.

Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD, Phogat A, Forsell MN, Karlsson Hedestam GB, Mascola JR, Wyatt RT.

J Biol Chem. 2012 Feb 17;287(8):5673-86. doi: 10.1074/jbc.M111.317776. Epub 2011 Dec 13.

3.

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.

Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.

5.

Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.

Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, Ward AB, Wilson IA, Sanders RW, Moore JP, Klasse PJ.

Retrovirology. 2014 May 29;11:41. doi: 10.1186/1742-4690-11-41.

6.

Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

Kim M, Qiao ZS, Montefiori DC, Haynes BF, Reinherz EL, Liao HX.

AIDS Res Hum Retroviruses. 2005 Jan;21(1):58-67.

PMID:
15665645
7.

Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.

Cheng C, Pancera M, Bossert A, Schmidt SD, Chen RE, Chen X, Druz A, Narpala S, Doria-Rose NA, McDermott AB, Kwong PD, Mascola JR.

J Virol. 2015 Dec 30;90(6):2740-55. doi: 10.1128/JVI.02380-15.

9.

Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.

Patil S, Kumar R, Deshpande S, Samal S, Shrivastava T, Boliar S, Bansal M, Chaudhary NK, Srikrishnan AK, Murugavel KG, Solomon S, Simek M, Koff WC, Goyal R, Chakrabarti BK, Bhattacharya J.

J Virol. 2016 Jan 13;90(7):3446-57. doi: 10.1128/JVI.03090-15.

10.

Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.

Grundner C, Li Y, Louder M, Mascola J, Yang X, Sodroski J, Wyatt R.

Virology. 2005 Jan 5;331(1):33-46.

11.

Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.

Trott M, Weiβ S, Antoni S, Koch J, von Briesen H, Hust M, Dietrich U.

PLoS One. 2014 May 14;9(5):e97478. doi: 10.1371/journal.pone.0097478. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e107089.

12.

Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, Seaman MS, Montefiori DC, Lagerquist E, Stamatatos L.

J Virol. 2012 Jan;86(1):128-42. doi: 10.1128/JVI.06363-11. Epub 2011 Oct 26.

13.

HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.

Bower JF, Li Y, Wyatt R, Ross TM.

Vaccine. 2006 Jun 29;24(26):5442-51. Epub 2006 Apr 3.

PMID:
16621193
14.

Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures.

Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang YK, Depetris R, Marozsan AJ, Sanders RW, Klasse PJ, Milne JL, Wilson IA, Olson WC, Moore JP, Subramaniam S.

Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11440-5. doi: 10.1073/pnas.1101414108. Epub 2011 Jun 27.

15.

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, Miller CA, Seaman MS, Barouch DH, Chen B.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):12111-6. doi: 10.1073/pnas.1204533109. Epub 2012 Jul 5.

16.

Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.

Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC, Berkhout B, Binley JM, Moore JP, Sanders RW.

J Virol. 2012 Mar;86(5):2488-500. doi: 10.1128/JVI.06259-11. Epub 2011 Dec 28.

17.

Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization.

Quinnan GV Jr, Onabajo O, Zhang P, Yan L, Mattapallil JJ, Zhang Z, Dong M, Lu M, Montefiori D, LaBranche C, Broder CC.

PLoS One. 2014 May 20;9(5):e98060. doi: 10.1371/journal.pone.0098060. eCollection 2014.

18.

Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.

Richmond JF, Mustafa F, Lu S, Santoro JC, Weng J, O'Connell M, Fenyö EM, Hurwitz JL, Montefiori DC, Robinson HL.

Virology. 1997 Apr 14;230(2):265-74.

19.

Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties.

Guenaga J, de Val N, Tran K, Feng Y, Satchwell K, Ward AB, Wyatt RT.

PLoS Pathog. 2015 Jan 8;11(1):e1004570. doi: 10.1371/journal.ppat.1004570. eCollection 2015 Jan.

20.

High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM.

Virology. 2009 May 10;387(2):414-26. doi: 10.1016/j.virol.2009.02.022. Epub 2009 Mar 18.

Supplemental Content

Support Center